Debt-free and still delivering: Why WAM is backing Pro Medicus despite big sell-off

At a time when we're seeing pronounced divergence in performance across individual stocks and sectors, it's clear this reporting season is another in which investors are adopting a take no prisoners approach. 

Pro Medicus (ASX: PME) has become the latest casualty, crashing more than 20% on a particularly savage day for companies delivering underwhelming results.

For Wilson Asset Management's Tobias Yao, there's a clear disconnect between investor sentiment in the short-term and the long-term opportunity PME is still offering investors.

Key takeaways

• Revenue up 28.4% to $124.8m vs $128.6m ests (3% miss)
• Underlying profit before tax up 29.7% to $90.7m, unclear if comparable to Macquarie pre-tax profit (Jan-26) ests of $101.8m
• Underlying EBIT margins up 100 bps to 73%

• Reported net profit after tax up 230.9% to $171.2m

• This includes unrealised gains of $149.1m from the company's $10m hybrid debt and equity investment in 4DMedical
• Cash and cash equivalents up 5.3% to $221.8m
• Interim dividend of 32 cps vs. Macquarie ests of 35 cps (8.5% miss)

Do you currently hold the stock and what is your rating?

Despite the sharp share price reaction, we continue to view Pro Medicus as a high-quality business with strong competitive advantages and recurring revenue growth prospects. 

Several brokers have maintained bullish ratings and high target prices following the release, underscoring the long-term opportunity even if near-term sentiment is weak.

What matters from the results?

• Revenue growth – Pro Medicus reported $124.8 m in first-half revenue, up ~28 % year-on-year, highlighting continued demand for its enterprise imaging and RIS products.
• Underlying profit growth – Underlying profit before tax rose ~29.7 % to $90.7 m, demonstrating solid profitability and margin stability in a high-margin software business.
• Contract momentum and pipeline – The company announced seven new contracts with a combined minimum value exceeding $280m, including large multi-year deals with significant US health systems and renewals, reinforcing the demand for Visage products.

Other notable metrics included cash and investments increasing to $221.8m, a fully-franked interim dividend of 32cps, and the company remaining debt-free.

How do those outcomes affect the medium-term outlook for Pro Medicus?

We maintain a positive outlook over the medium term. We believe that while the sentiment is negative in the short term around AI disruption, PME is very well placed as a beneficiary of AI.

What should investors be paying attention to as the story unfolds?

There's a few upside drivers:

• Continued contract wins and implementations – Securing and successfully deploying additional large multi-year contracts (especially in the US), will drive recurring revenue growth and widen the company’s installed base.
• Cross-sell and product expansion – Moving beyond core radiology into adjunct specialties (e.g., cardiology) and broader health IT workflows could unlock additional revenue streams.

And also some risks:

• Valuation risk and market expectations – Given past premium multiples, any modest miss relative to high growth expectations can cause outsized price reactions (as seen today).
• Competitive pressure and execution noise – Competitive responses from larger incumbents or evolving customer preferences could pressure contract wins or the pace of market share gains.

A good analyst knows where their blind spots are: What could you be wrong about?

Competitive dynamics in enterprise imaging: There is limited visibility into what emerging competitors (especially private AI-enabled imaging platforms) are developing. Should a new entrant materially alter the adoption landscape or erode perceived product differentiation, demand could slow faster than forecasted.

Market pricing of AI opportunities: While management emphasised that AI is a complement to Visage software, the market may be pricing AI disruption differently. If AI tools commoditise core imaging workflows faster than expected, it could affect long-term pricing power and growth.